mRNA-1273 vaccine

BIOLOGICAL3 trials

Sponsors

University Health Network, Toronto, Merck Sharp & Dohme LLC, Sheba Medical Center

Conditions

COVID-19COVID-19 PandemicCoronavirus Disease (COVID-19)Covid19Immune SuppressionImmunogenicityPapillomavirus InfectionsSARS CoV 2 Infection

Phase 2

Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults

CompletedNCT05383560

Sheba Medical CenterCOVID-19, COVID-19 Pandemic, Immunogenicity +1

Start: 2022-09-05End: 2024-01-31Updated: 2024-02-21

Phase 3

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

CompletedNCT05119855

Merck Sharp & Dohme LLCCoronavirus Disease (COVID-19), Papillomavirus Infections

Start: 2022-03-28End: 2023-12-12Updated: 2026-02-05

Phase 4

Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients

CompletedNCT04885907

University Health Network, TorontoCovid19, Immune Suppression, Vaccine Response Impaired

Start: 2021-05-25End: 2021-08-30Updated: 2022-08-02

Related Papers

Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.

2021-11-2347 citations